← Back to Search

Antisense Oligonucleotide

CDK-004 for Liver Cancer

Phase 1
Waitlist Available
Research Sponsored by Codiak BioSciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights

Study Summary

This trial is testing a new drug to treat advanced liver cancer. The drug will be given to a small group of people to see if it is safe and effective.

Eligible Conditions
  • Liver Cancer
  • Gastric Cancer
  • Colorectal Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To characterize the safety and tolerability of CDK-004.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Experimental CDK-004Experimental Treatment1 Intervention
CDK-004 administered as a single agent intravenously (IV) on Days 1 and 15 of Cycles 1 and 2, on Day 1 of every Cycle.

Find a Location

Who is running the clinical trial?

Codiak BioSciencesLead Sponsor
2 Previous Clinical Trials
29 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How do the potential risks of CDK-004 compare to its therapeutic rewards?

"Our team at Power gave CDK-004 a score of 1 to reflect the fact that this trial is in its preliminary stages, and therefore, has only limited evidence supporting safety and efficacy."

Answered by AI

What is the current enrollment number for this research project?

"To partake in this clinical trial, 30 eligible candidates must be recruited from two distinct sites: Memorial Sloan Kettering Cancer Center located in New york City and Sarah Cannon Research Institute based out of Nashville."

Answered by AI

Are there still vacancies for people to participate in this clinical trial?

"Submissions to clinicaltrials.gov affirm that this research is actively searching for participants, with the trial having been initially posted on June 28th 2022 and updated as recently as August 29th of the same year."

Answered by AI

Who else is applying?

What state do they live in?
New York
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From EIther Primary Gastric Cancer or Colorectal Cancer (CRC)
2022. "A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From EIther Primary Gastric Cancer or Colorectal Cancer (CRC)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05375604.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top